Recombinant:Article Title: Overexpression of SerpinE2/protease nexin-1 Contribute to Pathological Cardiac Fibrosis via increasing Collagen Deposition.
Article Snippet: .. After starvation in serum-free medium for 24 h, 50 nM AngII (Sigma– Aldrich, St. Louis, MO, USA), or 10 ng/ml recombinant human TGF-β 1 protein (Sino Biological Inc., China), or 10 ng/ml recombinant human serpinE2 (Proteintech Inc., USA) were applied to cardiac fibroblasts, respectively, for 24 h and 48 h. Transfection shRNA SerpinE2, siRNA ERK-1 or siRNA Elk1. .. For transfection, cardiac fibroblasts were cultured with serum-free medium once and then incubated with serum-free medium for 6 h. The shRNA serpinE2 (PN-1 shRNA Plasmid (h): sc-45254-SH Santa Cruz Biotechnology Inc., USA), siRNA ERK-1 and siRNA Elk1 (Guangzhou RiboBio Co. Ltd., China), and X-treme GENE siRNA Transfection Reagent (Roche, USA) were mixed, respectively, with Opti-MEM® Reduced Serum Medium (Gibco, Grand Island, NY), and then cardiac fibroblast were treated with each mix for transfection, according to the manufacturer’s protocol.
Article Title: Overexpression of SerpinE2/protease nexin-1 Contribute to Pathological Cardiac Fibrosis via increasing Collagen Deposition
Article Snippet: .. After starvation in serum-free medium for 24 h, 50 nM AngII (Sigma–Aldrich, St. Louis, MO, USA), or 10 ng/ml recombinant human TGF-β1 protein (Sino Biological Inc., China), or 10 ng/ml recombinant human serpinE2 (Proteintech Inc., USA) were applied to cardiac fibroblasts, respectively, for 24 h and 48 h. .. For transfection, cardiac fibroblasts were cultured with serum-free medium once and then incubated with serum-free medium for 6 h. The shRNA serpinE2 (PN-1 shRNA Plasmid (h): sc-45254-SH Santa Cruz Biotechnology Inc., USA), siRNA ERK-1 and siRNA Elk1 (Guangzhou RiboBio Co. Ltd., China), and X-treme GENE siRNA Transfection Reagent (Roche, USA) were mixed, respectively, with Opti-MEM ® Reduced Serum Medium (Gibco, Grand Island, NY), and then cardiac fibroblast were treated with each mix for transfection, according to the manufacturer’s protocol.
Transfection:Article Title: Overexpression of SerpinE2/protease nexin-1 Contribute to Pathological Cardiac Fibrosis via increasing Collagen Deposition.
Article Snippet: .. After starvation in serum-free medium for 24 h, 50 nM AngII (Sigma– Aldrich, St. Louis, MO, USA), or 10 ng/ml recombinant human TGF-β 1 protein (Sino Biological Inc., China), or 10 ng/ml recombinant human serpinE2 (Proteintech Inc., USA) were applied to cardiac fibroblasts, respectively, for 24 h and 48 h. Transfection shRNA SerpinE2, siRNA ERK-1 or siRNA Elk1. .. For transfection, cardiac fibroblasts were cultured with serum-free medium once and then incubated with serum-free medium for 6 h. The shRNA serpinE2 (PN-1 shRNA Plasmid (h): sc-45254-SH Santa Cruz Biotechnology Inc., USA), siRNA ERK-1 and siRNA Elk1 (Guangzhou RiboBio Co. Ltd., China), and X-treme GENE siRNA Transfection Reagent (Roche, USA) were mixed, respectively, with Opti-MEM® Reduced Serum Medium (Gibco, Grand Island, NY), and then cardiac fibroblast were treated with each mix for transfection, according to the manufacturer’s protocol.
shRNA:Article Title: Overexpression of SerpinE2/protease nexin-1 Contribute to Pathological Cardiac Fibrosis via increasing Collagen Deposition.
Article Snippet: .. After starvation in serum-free medium for 24 h, 50 nM AngII (Sigma– Aldrich, St. Louis, MO, USA), or 10 ng/ml recombinant human TGF-β 1 protein (Sino Biological Inc., China), or 10 ng/ml recombinant human serpinE2 (Proteintech Inc., USA) were applied to cardiac fibroblasts, respectively, for 24 h and 48 h. Transfection shRNA SerpinE2, siRNA ERK-1 or siRNA Elk1. .. For transfection, cardiac fibroblasts were cultured with serum-free medium once and then incubated with serum-free medium for 6 h. The shRNA serpinE2 (PN-1 shRNA Plasmid (h): sc-45254-SH Santa Cruz Biotechnology Inc., USA), siRNA ERK-1 and siRNA Elk1 (Guangzhou RiboBio Co. Ltd., China), and X-treme GENE siRNA Transfection Reagent (Roche, USA) were mixed, respectively, with Opti-MEM® Reduced Serum Medium (Gibco, Grand Island, NY), and then cardiac fibroblast were treated with each mix for transfection, according to the manufacturer’s protocol.
|